More than 11,000 bottles of chlorthalidone, a blood pressure medication, are being recalled nationwide due to a manufacturing defect causing failed dissolution specifications. The recall was voluntarily initiated by Inventia Healthcare Limited and covers specific batches distributed in the U.S. by Rising Pharma Holdings. Chlorthalidone is used to treat high blood pressure and reduce swelling related to heart, kidney, or liver disease. The recall affects bottles with batch codes RISA24001 and RISB24002, expiring in April 2027, and is ongoing as per the FDA.
The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...
argenx, a global immunology company, is hosting a webinar on June 23, 2026, focused on advancing research and development of FcRn blockers for autoimmune myositis. The event features argenx's management and scientific leaders alongside key external e...
Signify announced a new strategy at its 2026 Capital Markets Day to become a more focused and better-performing company by 2029. The plan includes prioritizing growth in connected lighting and consumer segments while optimizing less profitable areas....
The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...
Akkodis' 2026 study reveals CTO confidence in scaling AI has fallen from 82% in 2024 to 48% in 2026, despite rapid AI adoption and increased investments. The main challenge is not technology but integrating AI into company systems, processes, and dec...
